Information Provided By: 
Fly News Breaks for July 31, 2015
MDXG
Jul 31, 2015 | 07:06 EDT
Brean Capital said MiMedx reported solid Q2 results and reiterated its full year revenue guidance. The firm noted the company revenue growth, continued sales force expansion, and new investment in its Collafix technology which will be its next commercial platform. Brean Capital reiterated its Buy rating and $16 price target on MiMedx shares.
News For MDXG From the Last 2 Days
There are no results for your query MDXG
